On Apr. 6, 2020, VGX announced successful implementation of new RNA production services through completion of all Phase II initiatives as part of a license agreement with the Houston Methodist Research Institute. The company has established pilot mRNA manufacturing capabilities in a purpose built GMP production suite at its current facility in The Woodlands, Texas.

A full range of capabilities have been developed to support client projects from initial plasmid DNA construction through linearization, in vitro translation, mRNA purification, and comprehensive quality control testing. Launch of clinical grade mRNA manufacturing is anticipated in 2020.